Cure51 clinches €15M to study cancer’s ‘exceptional survivors’

21 Mar 2024
firstwordpharma.com
Aiming to learn more about those who overcome particularly aggressive forms of cancer, Cure51 raised €15 million ($16.4 million) in a seed round led by Sofinnova Partners.
Other investors in the fundraising include Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Datadog co-founder and CEO Olivier Pomel.
Founded in 2022, Cure51 is building a clinical and molecular database of “exceptional” cancer survivors, against which it is deploying new analytical techniques to investigate the molecular means by which the patients are able to live for long periods of time.
“Modern AI models require world class datasets to uncover novel biology and discover transformative medicines, and this is what Cure51 is uniquely creating for cancer patients,” said Hitachi’s Joanna Soroka.
Cure51 is working with five oncology centres in Europe: the Gustave Roussy Institute in Paris, the Leon Bérard Center in Lyon, the Charité Universitätsmedizin in Berlin, the Instituto Europeo di Oncologia in Milan, and the Vall d'Hebron in Barcelona.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.